GlassScriptPhysician profile
Sarah E Champion
NPI 1316053457
$2,797.44
in general payments reported to CMS, 2019-2025
25 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,582 · 2022: $971 · 2023: $14.94 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $795.49 | 2021-2022 | |
| Abbvie INC. | $318.79 | 2021-2025 | |
| Emd Serono, INC. | $300.02 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $296.82 | 2021-2022 | |
| Nevro Corp. | $140.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $122.92 | 2021-2025 | Ajovy |
| Sunovion Pharmaceuticals INC. | $109.20 | 2021 | |
| Argenx US, INC. | $70.26 | 2025 | Vyvgart Hytrulo |
| Genzyme Corporation | $70.25 | 2022-2025 | |
| Celgene Corporation | $66.57 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $58.18 | 2021-2022 | |
| Lilly USA, LLC | $53.03 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $45.90 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.92 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $40.68 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $37.23 | 2021-2022 | |
| Genentech USA, INC. | $35.97 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $35.71 | 2021 | |
| Allergan, INC. | $32.51 | 2021-2022 | |
| Tg Therapeutics, INC. | $31.09 | 2025 | |
| Merz Pharmaceuticals, LLC | $20.84 | 2025 | Ampyra, Inbrija, Xeomin |
| Genentech, INC. | $20.24 | 2025 | Ocrevus |
| Sanofi-Aventis U.S. LLC | $19.83 | 2021 | |
| Amgen INC. | $18.72 | 2021 | |
| Acadia Pharmaceuticals INC | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Champion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.